Ostatní
Návod 
AbbVie Inc.
ABBV
Souhrn
Výkazy
Ukazatele
Profil
Držitelé
Návštěvnost webu
Konkurence
Zprávy společnosti
Kapitalizace
383.4B
Obrat
61B
Zisk
4B
Aktiva
134B
Dluh
69B
ROE
0%
ROA
0%
PE
86
PS
6
Cena 1R
164-245
⌀ Cena
206.87
Dividenda
0.0(0.0%)
Čtvrtletní 10-Q
Celoroční 10-K
Nadcházející oznámení zisků
24-04-2026
Nadcházející dividenda
15-04-2026
Profil
AbbVie Inc. objevuje, vyvíjí, vyrábí a prodává léčiva po celém světě. Společnost nabízí přípravek HUMIRA, terapii podávanou jako injekce k léčbě autoimunitních a střevních Behçetových chorob; SKYRIZI k léčbě středně těžké až těžké ložiskové psoriázy u dospělých; RINVOQ, inhibitor JAK k léčbě středně těžké až těžké aktivní revmatoidní artritidy u dospělých pacientů; IMBRUVICA k léčbě dospělých pacientů s chronickou lymfocytární leukémií (CLL), malým lymfocytárním lymfomem (SLL) a VENCLEXTA, inhibitor BCL- 2 používaný k léčbě dospělých s CLL nebo SLL; a MAVYRET k léčbě pacientů chronická infekce HCV genotypu 1- 6. Poskytuje také CREON, pankreatickou enzymatickou terapii pro exokrinní pankreatickou insuficienci; Syntroid užívaný při léčbě hypotyreózy; Linzess/Constella k léčbě syndromu dráždivého střeva se zácpou a chronickou idiopatickou zácpou; Lupron k paliativní léčbě pokročilého karcinomu prostaty, endometriózy a centrální prekožní puberty, a pacientům s anémií způsobenou děložními fibroidy; a Botox terapeutické. Společnost dále nabízí ORILISSA, antagonistu nepeptidového malého molekulového gonadotropinu uvolňujícího hormonu pro ženy se středně těžkou až těžkou bolestí endometriózy; Duopa a Duodopa, střevní gel levodopa-karbidopy k léčbě Parkinsonovy choroby; Lumigan/Ganfort, oční roztok bimatoprostu ke snížení zvýšeného nitroočního tlaku (IOP) u pacientů s glaukomem s otevřeným úhlem (OAG) nebo oční hypertenzí; Ubrelvy k léčbě migrény s nebo bez něj aura u dospělých; Alphagan/Combigan, agonista alfa-adrenergních receptorů ke snížení nitroočního tlaku u pacientů s OAG; a Restasis, imunosupresivum inhibitoru kalcineurinu ke zvýšení tvorby slz, stejně jako další přípravky pro péči o oči. AbbVie Inc. spolupracuje s firmou Dragonfly Therapeutics, Inc. Společnost byla založena v roce 2012 a sídlí v severním Chicagu ve státě Illinois.
Sektor
Healthcare
Odvětví
Drug Manufacturers - General
Počet zaměstnanců
55000
Založení
2013-01-02
Podobné společnosti
$ 187.28
+ $ 0.71
$ 86.08
+ $ 1.50
$ 126.72
+ $ 0.37
$ 45.70
+ $ 0.02
$ 86.23
- $ 0.05
$ 322.60
- $ 1.61
$ 321.61
+ $ 1.41
Zahraniční články
Výsledovka
Rozvaha
Peněžní toky
Výsledovka
Výsledovka
Rozvaha
Peněžní toky
V miliardách (USD)
| Revenue | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenues | 61.16 | 61.16 | 56.33 | 54.32 | 58.05 | 56.20 | 45.80 | 33.27 | 32.75 | 28.22 | 25.64 | 22.86 | 19.96 | 18.79 | 18.38 | 17.44 | 15.64 | |
| Cost of Revenues | 16.31 | 9.97 | 16.90 | 20.42 | 17.41 | 17.45 | 15.39 | 7.44 | 7.72 | 7.04 | 5.83 | 4.50 | 4.43 | 4.58 | 4.51 | 4.64 | 4.29 | |
| Gross Profit | 44.85 | 51.20 | 39.43 | 33.90 | 40.64 | 38.75 | 30.42 | 25.83 | 25.04 | 21.18 | 19.81 | 18.36 | 15.53 | 14.21 | 13.87 | 12.80 | 11.35 |
| Revenue | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenues | 16.62 | 15.78 | 15.42 | 13.34 | 15.10 | 14.46 | 14.46 | 12.31 | 14.30 | 13.93 | |
| Cost of Revenues | 2.66 | 5.30 | 4.35 | 4.00 | 4.40 | 4.21 | 4.20 | 4.09 | 2.39 | 6.49 | |
| Gross Profit | 13.96 | 10.47 | 11.08 | 9.34 | 10.71 | 10.25 | 10.26 | 8.22 | 11.92 | 7.44 |
| Operating Income | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | 0.00 | 0.00 | 0.00 | 8.45 | 6.51 | 7.08 | 6.56 | 6.41 | 10.33 | 4.98 | 4.37 | 4.29 | 3.30 | 2.86 | 2.78 | 2.62 | 2.50 | |
| Selling General & Admin Expenses | 0.00 | 0.00 | 0.00 | 12.87 | 15.26 | 12.35 | 11.30 | 6.94 | 7.40 | 6.28 | 5.86 | 6.39 | 7.72 | 5.35 | 4.99 | 5.89 | 3.82 | |
| Depreciation & Amortization | 18.86 | 19.07 | 8.39 | 8.70 | 8.47 | 8.52 | 6.47 | 0.81 | 1.77 | 1.50 | 1.19 | 0.84 | 0.79 | 0.90 | 1.15 | 1.27 | 1.18 | |
| Total Operating Expenses | 28.51 | 29.98 | 30.29 | 21.15 | 21.83 | 19.87 | 17.86 | 12.46 | 18.23 | 11.26 | 10.22 | 10.67 | 11.77 | 8.21 | 7.77 | 8.51 | 6.32 | |
| Operating Income | 16.34 | 21.21 | 9.14 | 12.76 | 18.12 | 17.92 | 0.48 | 12.98 | 6.38 | 9.59 | 9.38 | 7.54 | 3.41 | 5.66 | 5.82 | 3.62 | 4.72 |
| Operating Income | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.92 | 1.72 | ||
| Selling General & Admin Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.61 | 3.37 | ||
| Depreciation & Amortization | 12.71 | 2.06 | 2.05 | 2.04 | 2.10 | 2.08 | 2.13 | 2.07 | 2.08 | 2.24 | ||
| Total Operating Expenses | 8.15 | 8.57 | 6.18 | 5.61 | 12.20 | 6.42 | 6.26 | 5.42 | 7.42 | 5.10 | ||
| Operating Income | 5.81 | 1.90 | 4.89 | 3.73 | -1.49 | 3.83 | 4.00 | 2.80 | 3.20 | 2.28 |
| Net Income | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest Income | 0.21 | 0.00 | 0.65 | 0.54 | 0.19 | 0.04 | 0.17 | 0.28 | 0.20 | 0.15 | 0.08 | 0.03 | 0.04 | 0.02 | 0.02 | 0.00 | 0.03 | |
| Interest Expense | 2.83 | 2.63 | 2.81 | 2.22 | 2.23 | 2.38 | 2.28 | 1.51 | 1.14 | 1.00 | 0.97 | 0.69 | 0.39 | 0.28 | 0.10 | 0.00 | 0.00 | |
| Other Expense | -9.74 | -14.62 | -5.42 | -6.51 | -3.29 | -3.51 | 2.92 | -4.56 | -0.47 | -1.19 | -0.74 | -0.36 | -1.00 | -0.39 | -0.30 | -0.62 | -0.22 | |
| IBT | 6.60 | 6.60 | 3.72 | 6.25 | 13.48 | 12.99 | 3.40 | 8.43 | 5.20 | 7.73 | 7.88 | 6.65 | 2.37 | 5.33 | 5.73 | 3.67 | 4.84 | |
| Income Tax Expense | 2.36 | 2.36 | -0.57 | 1.38 | 1.63 | 1.44 | -1.22 | 0.54 | -0.49 | 2.42 | 1.93 | 1.50 | 0.60 | 1.20 | 0.45 | 0.24 | 0.66 | |
| Net Income | 4.23 | 4.23 | 4.28 | 4.86 | 11.84 | 11.54 | 4.62 | 7.88 | 5.69 | 5.31 | 5.95 | 5.14 | 1.77 | 4.13 | 5.28 | 3.43 | 4.18 |
| Net Income | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest Income | 0.00 | 0.07 | 0.06 | 0.07 | 0.09 | 0.13 | 0.22 | 0.21 | 0.19 | 0.16 | ||
| Interest Expense | 0.66 | 0.74 | 0.74 | 0.70 | 0.70 | 0.72 | 0.73 | 0.66 | 0.56 | 0.56 | ||
| Other Expense | -3.14 | -1.19 | -3.34 | -2.07 | -0.78 | -1.75 | -1.85 | -1.04 | -1.98 | -0.33 | ||
| IBT | 2.67 | 0.71 | 1.55 | 1.66 | -2.27 | 2.08 | 2.15 | 1.76 | 1.21 | 1.95 | ||
| Income Tax Expense | 0.85 | 0.53 | 0.61 | 0.37 | -2.25 | 0.52 | 0.77 | 0.38 | 0.39 | 0.17 | ||
| Net Income | 1.82 | 0.19 | 0.94 | 1.29 | -0.02 | 1.56 | 1.37 | 1.37 | 0.82 | 1.78 |
| Per Share Data | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS | $0.00 | $0.00 | $0.00 | $2.73 | $6.65 | $6.48 | $2.73 | $5.30 | $3.69 | $3.31 | $3.65 | $3.15 | $1.11 | $2.58 | $3.35 | $2.12 | $2.59 | |
| EPS Diluted | $0.00 | $0.00 | $0.00 | $2.72 | $6.63 | $6.45 | $2.72 | $5.28 | $3.68 | $3.30 | $3.63 | $3.13 | $1.10 | $2.56 | $3.35 | $2.11 | $2.57 | |
| Shares Outstanding | 1.78 | 1.79 | 1.77 | 1.77 | 1.77 | 1.77 | 1.67 | 1.48 | 1.54 | 1.60 | 1.62 | 1.63 | 1.60 | 1.59 | 1.58 | 1.62 | 1.62 | |
| Diluted Shares Outstanding | 1.77 | 1.79 | 1.77 | 1.77 | 1.78 | 1.78 | 1.67 | 1.48 | 1.55 | 1.60 | 1.63 | 1.64 | 1.61 | 1.60 | 1.58 | 1.63 | 1.63 |
| Per Share Data | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.46 | $1.00 | ||
| EPS Diluted | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.46 | $1.00 | ||
| Shares Outstanding | 1.78 | 1.77 | 1.77 | 1.77 | 1.77 | 1.77 | 1.77 | 1.77 | 1.77 | 1.77 | ||
| Diluted Shares Outstanding | 1.77 | 1.77 | 1.77 | 1.77 | 1.77 | 1.77 | 1.77 | 1.77 | 1.77 | 1.77 |
| Current Assets | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Equivalents | 13.13 | 5.52 | 12.81 | 9.20 | 9.75 | 8.45 | 39.92 | 7.29 | 9.30 | 5.10 | 8.40 | 8.35 | 9.60 | 5.90 | 0.03 | 0.01 | |
| Short Term Investments | 0.03 | 0.03 | 0.00 | 0.03 | 0.08 | 0.03 | 0.00 | 0.77 | 0.49 | 1.32 | 0.01 | 0.03 | 0.30 | 2.08 | 0.63 | 0.00 | |
| Total Cash & ST Investments | 13.16 | 5.56 | 12.82 | 9.23 | 9.83 | 8.48 | 39.92 | 8.06 | 9.79 | 6.42 | 8.41 | 8.37 | 9.90 | 7.98 | 0.65 | 0.01 | |
| Accounts Receivable | 11.72 | 10.92 | 11.16 | 11.25 | 9.98 | 8.82 | 5.43 | 5.38 | 5.09 | 4.76 | 4.73 | 4.29 | 4.80 | 4.30 | 3.82 | 3.37 | |
| Inventory | 4.22 | 4.18 | 4.10 | 3.58 | 3.13 | 3.31 | 1.81 | 1.61 | 1.61 | 1.44 | 1.72 | 1.12 | 1.15 | 1.09 | 0.87 | 0.84 | |
| Other Current Assets | 4.72 | 4.93 | 4.93 | 4.40 | 4.99 | 3.56 | 2.35 | 1.90 | 4.74 | 3.56 | 1.46 | 2.30 | 2.00 | 1.99 | 2.01 | 4.00 | |
| Total Current Assets | 33.82 | 25.58 | 33.00 | 28.46 | 27.93 | 24.17 | 49.52 | 16.95 | 21.22 | 16.19 | 16.31 | 16.09 | 17.85 | 15.35 | 7.35 | 8.22 |
| Current Assets | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Equivalents | 5.63 | 6.47 | 5.18 | 5.52 | 7.26 | 13.13 | 18.07 | 12.81 | 13.29 | 8.76 | |
| Short Term Investments | 0.04 | 0.00 | 0.00 | 0.03 | 0.03 | 0.03 | 0.00 | 0.00 | 0.00 | 0.01 | |
| Total Cash & ST Investments | 5.67 | 6.47 | 5.18 | 5.56 | 7.29 | 13.16 | 18.07 | 12.82 | 13.29 | 8.77 | |
| Accounts Receivable | 12.77 | 12.64 | 12.48 | 10.92 | 11.47 | 11.72 | 11.95 | 11.16 | 11.41 | 11.49 | |
| Inventory | 4.94 | 4.96 | 4.53 | 4.18 | 4.45 | 4.22 | 4.25 | 4.10 | 3.98 | 4.06 | |
| Other Current Assets | 5.16 | 5.20 | 5.50 | 4.93 | 4.58 | 4.72 | 4.61 | 4.93 | 4.54 | 4.54 | |
| Total Current Assets | 28.54 | 29.26 | 27.68 | 25.58 | 27.79 | 33.82 | 38.87 | 33.00 | 33.22 | 28.85 |
| Long-Term Assets | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Property, Plant & Equipment | 5.02 | 5.13 | 4.99 | 4.94 | 5.11 | 5.25 | 2.96 | 2.88 | 2.80 | 2.60 | 2.57 | 2.49 | 2.30 | 2.25 | 2.14 | 2.36 | |
| Goodwill | 33.39 | 34.96 | 32.29 | 32.16 | 32.38 | 33.12 | 15.60 | 15.66 | 15.79 | 15.42 | 13.17 | 5.86 | 6.28 | 6.13 | 6.10 | 6.20 | |
| Intangible Assets | 60.24 | 60.07 | 55.61 | 67.44 | 75.95 | 82.88 | 18.65 | 21.23 | 27.56 | 28.90 | 19.71 | 1.51 | 1.89 | 2.32 | 2.91 | 3.69 | |
| Long-Term Investments | 0.33 | 0.28 | 0.30 | 0.24 | 0.28 | 0.29 | 0.09 | 1.42 | 2.09 | 1.78 | 0.15 | 0.09 | 0.12 | 0.12 | 0.23 | 0.14 | |
| Other Long-Term Assets | 6.42 | 9.14 | 8.51 | 3.38 | 1.88 | 1.21 | 1.16 | 0.14 | -1.16 | -5.68 | -4.13 | 0.61 | 0.77 | 0.84 | 0.00 | 0.00 | |
| Total Long-Term Assets | 108.12 | 109.58 | 101.71 | 110.34 | 118.60 | 126.39 | 39.60 | 42.41 | 49.56 | 49.91 | 36.74 | 11.46 | 11.35 | 11.65 | 12.30 | 12.92 | |
| Total Assets | 141.94 | 135.16 | 134.71 | 138.81 | 146.53 | 150.57 | 89.12 | 59.35 | 70.79 | 66.10 | 53.05 | 27.55 | 29.20 | 27.01 | 19.66 | 21.13 |
| Long-Term Assets | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Property, Plant & Equipment | 5.48 | 5.28 | 5.24 | 5.13 | 5.14 | 5.02 | 4.98 | 4.99 | 4.93 | 4.94 | |
| Goodwill | 35.63 | 35.64 | 35.29 | 34.96 | 35.30 | 33.39 | 33.43 | 32.29 | 32.09 | 32.22 | |
| Intangible Assets | 54.32 | 57.03 | 58.49 | 60.07 | 66.65 | 60.24 | 62.23 | 55.61 | 58.60 | 62.86 | |
| Long-Term Investments | 0.29 | 0.31 | 0.29 | 0.28 | 0.27 | 0.27 | 0.31 | 0.30 | 0.28 | 0.29 | |
| Other Long-Term Assets | 9.64 | 9.66 | 9.19 | 9.14 | 8.29 | 9.20 | 9.07 | 8.51 | 7.09 | 6.20 | |
| Total Long-Term Assets | 105.36 | 107.92 | 108.49 | 109.58 | 115.64 | 108.12 | 110.00 | 101.71 | 103.00 | 106.52 | |
| Total Assets | 133.90 | 137.18 | 136.17 | 135.16 | 143.42 | 141.94 | 148.87 | 134.71 | 136.22 | 135.37 |
| Current Liabilities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 29.30 | 2.95 | 3.69 | 2.93 | 2.88 | 2.28 | 1.45 | 1.55 | 1.47 | 1.41 | 1.60 | 0.88 | 0.93 | 0.56 | 0.42 | 0.36 | |
| Short-Term Debt | 12.59 | 6.80 | 7.19 | 4.14 | 12.50 | 8.50 | 3.75 | 5.31 | 6.42 | 0.40 | 2.43 | 4.45 | 0.43 | 1.04 | 0.00 | 0.00 | |
| Other Current Liabilities | 0.03 | 29.00 | 26.96 | 22.47 | 19.82 | 17.88 | 10.38 | 10.39 | 8.75 | 7.97 | 6.87 | 6.07 | 5.52 | 5.18 | 5.48 | 3.40 | |
| Current Liabilities | 41.92 | 38.75 | 37.84 | 29.54 | 35.19 | 28.66 | 15.59 | 17.24 | 16.64 | 9.78 | 10.89 | 11.40 | 6.88 | 6.78 | 5.90 | 3.76 |
| Current Liabilities | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 0.00 | 31.83 | 30.96 | 31.91 | 30.40 | 29.30 | 31.26 | 3.69 | 0.00 | 0.00 | |
| Short-Term Debt | 5.77 | 7.52 | 5.36 | 6.80 | 12.57 | 12.59 | 10.20 | 7.19 | 5.12 | 5.20 | |
| Other Current Liabilities | 33.62 | 0.41 | 0.08 | 0.04 | 0.09 | 0.03 | 0.07 | 26.96 | 29.66 | 27.04 | |
| Current Liabilities | 39.39 | 39.77 | 36.40 | 38.75 | 43.06 | 41.92 | 41.52 | 37.84 | 34.77 | 32.24 |
| Long-Term Liabilities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | 58.05 | 61.06 | 52.96 | 59.14 | 64.19 | 77.55 | 62.98 | 35.00 | 30.95 | 36.44 | 29.24 | 10.57 | 14.29 | 14.63 | 0.00 | 0.00 | |
| Capital Leases | 0.00 | 0.92 | 0.76 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Def. Tax Liability | 2.73 | 7.63 | 0.00 | 2.19 | 3.01 | 3.65 | 1.13 | 1.07 | 2.49 | 6.89 | 5.28 | 0.63 | 0.57 | 0.36 | 0.00 | 0.00 | |
| Total Liabilities | 135.12 | 131.80 | 124.31 | 121.52 | 131.09 | 137.47 | 97.29 | 67.80 | 65.69 | 61.46 | 49.11 | 25.81 | 24.71 | 23.65 | 7.43 | 5.43 |
| Long-Term Liabilities | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | 62.97 | 62.96 | 64.53 | 61.06 | 58.51 | 58.05 | 63.81 | 52.96 | 55.63 | 55.81 | |
| Capital Leases | 0.00 | 0.00 | 0.00 | 0.92 | 0.00 | 0.00 | 0.00 | 0.76 | 0.00 | 0.00 | |
| Def. Tax Liability | 2.48 | 2.55 | 2.58 | 7.63 | 2.75 | 2.73 | 2.72 | 1.95 | 2.04 | 2.12 | |
| Total Liabilities | 136.50 | 137.32 | 134.70 | 131.80 | 137.35 | 135.12 | 140.83 | 124.31 | 124.09 | 122.47 |
| Total Common Equity | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 3.71 | 0.00 | 0.00 | |
| Retained Earnings | -3.77 | -7.90 | -1.00 | 4.78 | 3.13 | 1.06 | 4.72 | 3.37 | 5.46 | 4.38 | 2.25 | 0.54 | 1.57 | 0.00 | 0.00 | 0.00 | |
| Comprehensive Income | -2.51 | -1.93 | -2.31 | -2.20 | -2.90 | -3.12 | -3.60 | -2.48 | -2.73 | -2.59 | -2.56 | -2.03 | -0.44 | -0.35 | -0.03 | 0.29 | |
| Total Common Equity | 6.78 | 3.33 | 10.36 | 17.25 | 15.41 | 13.08 | -8.17 | -8.45 | 5.10 | 4.64 | 3.95 | 1.74 | 4.49 | 3.36 | 12.22 | 15.70 |
| Total Common Equity | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | |
| Retained Earnings | -14.23 | -11.50 | -9.53 | -7.90 | -4.96 | -3.77 | -2.38 | -1.00 | 0.93 | 1.79 | |
| Comprehensive Income | -1.57 | -1.54 | -1.74 | -1.93 | -2.33 | -2.51 | -2.45 | -2.31 | -2.35 | -2.25 | |
| Total Common Equity | -2.64 | -0.18 | 1.42 | 3.33 | 6.03 | 6.78 | 8.01 | 10.36 | 12.09 | 12.87 |
| Other | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Debt | 70.63 | 67.84 | 59.39 | 63.27 | 76.68 | 86.06 | 66.73 | 40.31 | 37.37 | 36.84 | 31.67 | 15.01 | 14.72 | 15.67 | 0.00 | 0.00 | |
| Book Value | 6.82 | 3.36 | 10.40 | 17.29 | 15.44 | 13.10 | -8.17 | -8.45 | 5.10 | 4.64 | 3.95 | 1.74 | 4.49 | 3.36 | 12.22 | 15.70 |
| Other | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Debt | 0.04 | 0.05 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.03 | |
| Book Value | -2.64 | -0.18 | 1.42 | 3.33 | 6.03 | 6.78 | 8.01 | 10.36 | 12.09 | 12.87 |
| Cash Flow From Operating Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 5.33 | 4.23 | 4.29 | 4.87 | 11.85 | 11.55 | 4.62 | 7.88 | 5.69 | 5.31 | 5.95 | 5.14 | 1.77 | 4.13 | 5.28 | 3.43 | 4.18 | |
| Depreciation & Amortization | 8.47 | 8.14 | 8.39 | 8.70 | 8.47 | 8.52 | 6.47 | 2.02 | 1.77 | 1.50 | 1.19 | 0.84 | 0.79 | 0.90 | 1.15 | 1.27 | 1.18 | |
| Stock-Based Compensation | 0.82 | 0.96 | 0.91 | 0.75 | 0.67 | 0.69 | 0.75 | 0.43 | 0.42 | 0.37 | 0.35 | 0.28 | 0.24 | 0.21 | 0.19 | 0.16 | 0.17 | |
| Change Working Capital | -0.05 | -2.36 | -2.78 | 2.81 | -0.26 | -1.32 | 0.11 | -1.33 | -1.13 | 0.01 | -1.69 | 0.50 | -0.79 | 0.66 | -0.62 | 0.71 | -0.87 | |
| Change In Accounts Receivable | -0.18 | -1.49 | 0.21 | 0.07 | -1.46 | -1.32 | -0.93 | -0.07 | -0.59 | -0.39 | -0.07 | -5.99 | -5.08 | -9.83 | 0.22 | -0.50 | -0.06 | |
| Change In Accounts Payable | 1.40 | 0.95 | 0.18 | 3.84 | 1.61 | 1.63 | 1.51 | -1.12 | 0.19 | 0.43 | -1.19 | 1.50 | -0.19 | -0.43 | -0.73 | 1.50 | -0.70 | |
| Change In Inventories | -0.09 | -0.23 | -0.32 | -0.42 | -0.69 | -0.14 | -0.04 | -0.23 | -0.23 | 0.09 | -0.04 | -0.43 | -0.20 | -0.06 | -0.20 | -0.09 | -0.07 | |
| Other Non-cash Items | 17.60 | 8.60 | 9.45 | 8.60 | 6.15 | 4.24 | 7.96 | 3.62 | 6.26 | 1.53 | 0.94 | 0.77 | 1.54 | 0.37 | 0.35 | 0.67 | 0.31 | |
| Cash from Operations | 18.64 | 0.00 | 0.00 | 22.84 | 24.94 | 22.78 | 17.59 | 13.32 | 13.43 | 9.96 | 7.04 | 7.54 | 3.55 | 6.27 | 6.35 | 6.25 | 4.98 |
| Cash Flow From Operating Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 1.82 | 0.19 | 0.94 | 1.29 | 4.29 | 1.59 | 1.37 | 1.36 | 0.83 | 1.78 | |
| Depreciation & Amortization | 1.99 | 2.06 | 2.05 | 2.04 | 2.10 | 2.08 | 2.13 | 2.07 | 2.08 | 2.24 | |
| Stock-Based Compensation | 0.16 | 0.21 | 0.18 | 0.41 | 0.67 | 0.18 | 0.22 | 0.35 | 0.13 | 0.13 | |
| Change Working Capital | -0.47 | 3.14 | -0.56 | -2.58 | -0.40 | 0.75 | -3.38 | 0.25 | 0.44 | 2.64 | |
| Change In Accounts Receivable | 0.16 | -0.16 | -0.02 | -1.48 | 0.39 | 0.34 | 0.18 | -0.70 | 0.34 | 0.00 | |
| Change In Accounts Payable | -0.60 | 1.73 | 0.52 | -0.70 | 1.25 | 0.27 | -1.70 | 0.36 | 0.18 | 2.55 | |
| Change In Inventories | -0.03 | 0.00 | -0.06 | -0.16 | -0.13 | -0.06 | -0.05 | -0.08 | 0.10 | -0.06 | |
| Other Non-cash Items | 2.13 | 1.23 | 2.82 | 0.51 | 1.15 | 1.12 | 1.95 | 0.40 | 2.67 | 1.65 | |
| Cash from Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.75 | 7.57 |
| Cash Flow From Investing Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Capital Expenditure | -0.86 | -1.21 | -0.97 | -0.78 | -0.70 | -0.79 | -0.80 | -0.55 | -0.64 | -0.53 | -0.48 | -0.53 | -0.61 | -0.49 | -0.33 | -0.36 | -0.45 | |
| Acquisitions | -10.75 | -0.20 | -17.49 | -1.22 | -0.79 | -1.90 | -39.61 | -1.14 | -0.74 | -0.31 | -2.76 | -12.45 | -0.62 | -0.41 | -0.69 | -0.27 | -2.62 | |
| Investments | -0.06 | -0.04 | -0.07 | -0.08 | -1.44 | -0.12 | -0.06 | -0.58 | -1.79 | -2.23 | -5.32 | -0.85 | -1.17 | -0.93 | -2.55 | -1.94 | -0.09 | |
| Sales of Investment | 0.03 | 0.08 | 0.56 | 0.06 | 1.53 | 0.10 | 1.53 | 2.70 | 2.16 | 2.79 | 2.36 | 0.88 | 1.48 | 2.71 | 1.15 | 1.25 | 0.00 | |
| Other Investing Activities | -1.06 | 0.00 | 0.00 | 0.01 | 0.77 | 0.37 | 1.39 | 0.17 | 0.00 | 0.00 | 0.12 | 0.02 | 0.00 | 0.00 | 0.00 | 1.87 | -1.87 | |
| Cash from Investing | -11.86 | 0.00 | 0.00 | -2.01 | -0.62 | -2.34 | -37.56 | 0.60 | -1.01 | -0.27 | -6.07 | -12.94 | -0.93 | 0.88 | -2.42 | 0.55 | -5.03 |
| Cash Flow From Investing Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Capital Expenditure | -0.33 | 0.50 | -0.27 | -0.24 | -0.29 | -0.25 | -0.24 | -0.19 | -0.21 | -0.22 | |
| Acquisitions | 0.00 | 1.27 | -0.94 | -0.54 | -1.79 | -8.29 | -0.84 | -9.39 | -0.55 | -0.16 | |
| Investments | -0.01 | -0.01 | -0.01 | -0.01 | -0.03 | -0.02 | -0.02 | -0.01 | -0.03 | -0.01 | |
| Sales of Investment | 0.03 | 0.00 | 0.01 | 0.03 | 0.04 | 0.51 | 0.00 | 0.01 | 0.01 | 0.01 | |
| Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.02 | 0.01 | |
| Cash from Investing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.80 | -0.37 |
| Cash Flow From Financing Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt Repaid | -19.91 | 0.00 | 0.00 | -4.15 | -14.43 | -9.41 | -5.68 | -5.24 | -6.04 | -0.03 | -6.01 | -4.02 | 0.00 | 0.00 | 0.00 | -0.02 | 0.00 | |
| Debt Issued | 29.53 | 67.84 | 8.46 | 0.26 | 1.02 | 0.04 | 25.01 | 31.65 | 8.98 | 0.55 | 11.18 | 20.68 | 0.29 | -0.95 | 15.67 | 0.02 | 0.00 | |
| Issuance of Common Stock | 0.20 | 0.00 | 0.00 | 0.00 | 0.00 | 1.24 | 3.21 | 31.49 | 9.34 | 0.28 | 11.87 | 20.78 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Repurchase of Common Stock | -1.34 | -0.98 | -1.71 | -1.97 | -1.49 | -0.93 | -0.98 | -0.63 | -12.01 | -1.41 | -6.03 | -7.57 | -0.65 | -0.32 | 0.00 | 0.00 | 0.00 | |
| Dividends Paid | -10.78 | 0.00 | 0.00 | -10.54 | -10.04 | -9.26 | -7.72 | -6.37 | -5.58 | -4.11 | -3.72 | -3.29 | -2.66 | -2.56 | 0.00 | 0.00 | 0.00 | |
| Other Financing Activities | -0.09 | 0.00 | 0.00 | -0.56 | 1.16 | -0.67 | -0.33 | -0.55 | -0.10 | -0.25 | -0.03 | -0.15 | 0.02 | -0.57 | 1.93 | -6.76 | 0.07 | |
| Cash from Financing | -2.39 | 0.00 | 0.00 | -17.22 | -24.80 | -19.04 | -11.50 | 18.71 | -14.40 | -5.51 | -3.93 | 5.75 | -3.29 | -3.44 | 1.93 | -6.78 | 0.07 |
| Cash Flow From Financing Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt Repaid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.79 | 0.00 | |
| Debt Issued | 68.74 | -1.74 | 0.59 | 2.05 | -3.24 | 0.45 | -3.37 | 14.62 | 0.43 | -0.27 | |
| Issuance of Common Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Repurchase of Common Stock | 0.00 | 0.00 | -0.01 | -0.96 | -0.36 | -0.02 | -0.01 | -1.32 | 0.00 | 0.00 | |
| Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -2.63 | -2.63 | |
| Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.03 | -0.03 | |
| Cash from Financing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -4.45 | -2.66 |
| Cash position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Change in Cash | 4.37 | -0.30 | -7.29 | 3.61 | -0.55 | 1.30 | -31.48 | 32.64 | -2.01 | 4.20 | -3.30 | 0.05 | -1.25 | 3.69 | 5.87 | 0.02 | 0.07 | |
| Closing Cash Balance | 13.13 | 5.23 | 5.52 | 12.81 | 9.20 | 9.75 | 8.45 | 39.92 | 7.29 | 9.30 | 5.10 | 8.40 | 8.35 | 9.60 | 5.90 | 0.03 | 0.01 |
| Cash position | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Change in Cash | -0.40 | -0.84 | 1.29 | -0.35 | -1.73 | -5.87 | -4.94 | 5.25 | -0.47 | 4.53 | |
| Closing Cash Balance | 5.23 | 5.63 | 6.47 | 5.18 | 5.52 | 7.26 | 13.13 | 18.07 | 12.81 | 13.29 |
| Free Cash Flow | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 17.78 | 17.82 | 17.83 | 22.06 | 24.25 | 21.99 | 16.79 | 12.77 | 12.79 | 9.43 | 6.56 | 7.00 | 2.94 | 5.78 | 6.01 | 5.89 | 4.53 | |
| Real Free Cash Flow | 16.96 | 16.86 | 16.92 | 21.32 | 23.58 | 21.30 | 16.04 | 12.34 | 12.37 | 9.07 | 6.21 | 6.72 | 2.70 | 5.56 | 5.83 | 5.73 | 4.36 |
| Free Cash Flow | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 4.89 | 7.53 | 4.88 | 1.40 | 6.76 | 5.20 | 2.03 | 3.85 | 4.55 | 7.36 | |
| Real Free Cash Flow | 4.73 | 7.32 | 4.71 | 0.99 | 6.08 | 5.02 | 1.81 | 3.50 | 4.42 | 7.23 |
Nacenění
Finance
Efektivita
Marže
Dividenda
Ostatní
Nacenění
| Ukazatel | Aktuální | Historické | Konkurence |
|---|---|---|---|
| P/E | 86.1 | 34.1 | 86.1 |
| P/S | 5.9 | 4.6 | 578 |
| P/B | -140 | -17.7 | 582.9 |
| P/FCF | 20.5 | 15.7 | 10581.1 |
| Market cap | $383.4 | $287.7 |
P/E (Price to Earnings Ratio) – Poměr ceny akcie k zisku za posledních 12 měsíců. Říká, kolik korun investor zaplatí za 1 korunu zisku. Např.: P/E = 15 znamená, že pokud akcie stojí 15 Kč, firma vydělala 1 Kč za poslední rok.
Finance
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Debt to Assets | 0 % | 47.8 % | 0 % |
| Debt to Income | 1626.7 % | 767.4 % | 0 % |
| Debt to Free cash flow | 387.4 % | 22.9 % | 0 % |
| Interest expense percentage | 17.3 % | 11.2 % | 7 % |
| Current ratio | 0.7 | 1.3 | 0 |
Efektivita
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| ROE | -160 % | 18.5 % | 0 % |
| ROA | 3.2 % | 8.4 % | 0 % |
| CapEx to Revenue | 0.5 % | 1.9 % | 10.5 % |
| RaD to Revenue | 0 % | 16.4 % | 0 % |
| ROEM | 1,112,000.0 | 762046.6 |
Marže
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Gross margin | 73.3 % | 74.1 % | 77.7 % |
| Operating margin | 26.7 % | 28.2 % | 29.4 % |
| Net margin | 6.9 % | 17.8 % | 22.3 % |
Dividenda
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Dividend yield | 0 % | 3 % | 0 % |
| Dividend payout percentage | 0 % | 93.4 % | 0 % |
Dividend yield (Dividendový výnos) ukazuje aktuální procentuální výnos z dividend vůči ceně akcie.
Ostatní
| Ukazatel | Aktuální | Historické |
|---|---|---|
| Shares outstanding | 1,774.0 mil | 1,657.0 mil |
| Employee count | 55.0 tis | 36.3 tis |
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
